PTIX - Earnings announcements

Transitioned from Pre-Clinical to Clinical Stage company in FY 2023Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized Anxiety Disorder, progressing through Phase 1 portionPlans to enroll final two out of five cohorts into the single dose portion of the Phase 1 trial within the next monthNEW YORK, NY / ACCESSWIRE / April 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today provided a corporate update and reported financial results for the fourth quarter and full year 2023."In 2023, Protagenic Therapeutics achieved a significant milestone as we began enrol

NEW YORK, NY / ACCESSWIRE / October 13, 2023 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced its FY 2022 annual shareholder meeting will be held Wednesday, December 13, 2023, at 10:00 am EST, for shareholders of record as of this coming Monday, October 16th.Those who would like to attend the meeting virtually may do so by going to the website www.virtualshareholdermeeting.com/PTIX2023. After the regular business of the shareholder is concluded, Executive Chairman Garo Armen, PhD., is expected to provide comments on the progress of the Company's ongoing Phase I clinical tria